Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer.
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
14
8
2020
medline:
19
8
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Local treatment of liver and/or lung metastases from colorectal cancer (CRC) is increasingly used in daily practice and comprises resection, radiofrequency ablation (RFA) and stereotactic radiotherapy (SBRT). The need for prognostic markers for patients undergoing such treatment is currently unmet. We investigated post-treatment circulating tumor-specific DNA (ctDNA) analysis and address a possible prognostic value in a pilot study. From July 2015 to September 2017, patients undergoing standard of care local treatment of liver and/or lung metastases were included in a prospective translational study. Blood samples were drawn 2 weeks after local treatment and during follow-up. CtDNA was detected by ddPCR and a mass spectrometry-based platform MassARRAY Post treatment blood samples were available for 35 patients including five with detectable ctDNA (KRAS mutation, The presence of ctDNA following local treatment of metastatic CRC is associated with an increased risk of recurrence and a short time to failure.
Sections du résumé
BACKGROUND
BACKGROUND
Local treatment of liver and/or lung metastases from colorectal cancer (CRC) is increasingly used in daily practice and comprises resection, radiofrequency ablation (RFA) and stereotactic radiotherapy (SBRT). The need for prognostic markers for patients undergoing such treatment is currently unmet. We investigated post-treatment circulating tumor-specific DNA (ctDNA) analysis and address a possible prognostic value in a pilot study.
MATERIALS
METHODS
From July 2015 to September 2017, patients undergoing standard of care local treatment of liver and/or lung metastases were included in a prospective translational study. Blood samples were drawn 2 weeks after local treatment and during follow-up. CtDNA was detected by ddPCR and a mass spectrometry-based platform MassARRAY
RESULTS
RESULTS
Post treatment blood samples were available for 35 patients including five with detectable ctDNA (KRAS mutation,
CONCLUSION
CONCLUSIONS
The presence of ctDNA following local treatment of metastatic CRC is associated with an increased risk of recurrence and a short time to failure.
Identifiants
pubmed: 32790489
doi: 10.1080/0284186X.2020.1806357
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM